Exact Sciences Q1 Revenues Tumble as it Awaits FDA Decision | GenomeWeb

NEW YORK (GenomeWeb) – Exact Sciences today announced a year-over-year tumble in its first quarter revenues as it awaits a decision by the US Food and Drug Administration on the company's colorectal cancer screening test.

The Madison, Wis.-based molecular diagnostics firm reported $294,000 in revenues for the three months ended March 31, down 71 percent from $1.0 million for the first quarter in 2013. The figure fell short of the consensus analyst revenue estimate of $600,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.